Closure beyond clozapine: successfully averting rebound symptoms in a patient with schizoaffective disorder and agranulocytosis
Summary‘Rebound’ or ‘withdrawal’ symptoms are frequently observed after a sudden discontinuation of clozapine. We describe a patient with treatment-resistant schizoaffective disorder who developed agranulocytosis on clozapine but was successfully switched to treatment with olanzapine with no deterio...
Main Authors: | Alastair Green, Thomas Stephenson, Eromona Whiskey, Sukhi S. Shergill |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2019-05-01
|
Series: | BJPsych Open |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S2056472419000310/type/journal_article |
Similar Items
-
Decoding Clozapine-Induced Agranulocytosis: Unraveling Interactions and Mitigation Strategies
by: Ali Alalawi, et al.
Published: (2024-06-01) -
Agranulocytosis and cardiac toxicity - serious side effects of clozapine
by: Ewa Krzewicka-Romaniuk, et al.
Published: (2019-09-01) -
Agranulocytosis and cardiac toxicity - serious side effects of clozapine
by: Ewa Krzewicka-Romaniuk, et al.
Published: (2019-09-01) -
Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis
by: Shusuke Numata, et al.
Published: (2018-09-01) -
Late onset clozapine induced agranulocytosis
by: Rajmohan Velayudhan, et al.
Published: (2014-01-01)